Welcome to our dedicated page for Catalyst Biosciences news (Ticker: cbio), a resource for investors and traders seeking the latest updates and insights on Catalyst Biosciences stock.
Catalyst Biosciences, Inc. (symbol: CBIO) is a clinical-stage biopharmaceutical company dedicated to developing novel medicines aimed at treating serious medical conditions. The company leverages its expertise in protease-based therapeutic candidates to create innovative solutions for patients who require new or improved treatment options.
Catalyst Biosciences' primary focus is on developing therapies for hemophilia, a genetic disorder that impairs the body's ability to control blood clotting. Hemophilia A and B are the two most common forms, and Catalyst is committed to innovating treatments that significantly improve the quality of life for those who suffer from this condition.
The company employs a rigorous scientific approach in its research and development efforts, harnessing the power of proteases—enzymes that cleave target proteins. This approach has enabled Catalyst to build a robust pipeline of therapeutic candidates that are currently undergoing various stages of clinical trials.
Recent achievements include promising clinical trial results, progressing their hemophilia therapies closer to potential regulatory approval, and forming strategic partnerships to enhance their research capabilities. These collaborations not only bolster Catalyst's scientific endeavors but also expand their reach in delivering cutting-edge treatments to patients globally.
Financially, Catalyst Biosciences continues to manage its resources prudently, securing necessary funding through equity offerings and strategic partnerships. Their focused investments aim at advancing their clinical programs while ensuring the financial stability needed to sustain long-term operations.
For the latest updates and relevant information about Catalyst Biosciences, Inc., including their recent news, ongoing projects, and financial performance, stay tuned to StockTitan's news section.
Catalyst Biosciences (NASDAQ:CBIO) announced the closing of an additional 485,000 shares at $5.75 each, netting approximately $2.8 million. The company aims to use these funds for general corporate needs, including research and development in hemophilia and complement programs, capital expenditures, and working capital.
Piper Sandler & Co. and Raymond James & Associates acted as bookrunners for the offering. This transaction follows an effective registration statement filed with the SEC in February 2019.
Catalyst Biosciences (NASDAQ: CBIO) announced positive pre-clinical findings for Marzeptacog alfa (activated) – MarzAA, at the EAHAD Congress on February 3, 2021. The next-gen engineered coagulation Factor VII demonstrated significant efficacy in controlling spontaneous bleeding in Hemophilia A rats and dogs. Most subjects required only a single subcutaneous dose for effective management. MarzAA is advancing to a Phase 3 trial for hemophilia patients. Catalyst aims to address unmet needs in bleeding disorders with its innovative therapies.
Catalyst Biosciences (NASDAQ:CBIO) has successfully closed an underwritten public offering of 8,700,000 shares at $5.75 each, raising approximately $50 million in gross proceeds. The funds will support general corporate purposes, including R&D in hemophilia and complement programs like MarzAA and CB 4332. The offering utilized an effective shelf registration with the SEC, showcasing Catalyst's ongoing commitment to address rare disorders. Piper Sandler & Co. served as the lead bookrunner for this offering.
Catalyst Biosciences, Inc. (NASDAQ:CBIO) announced a public offering of 8,700,000 shares at $5.75 each, with expected gross proceeds of $50 million. The offering includes a 30-day option for underwriters to purchase an additional 1,305,000 shares. Proceeds will support general corporate purposes, focusing on hemophilia and complement programs, including MarzAA and CB 4332. The offering is anticipated to close on January 29, 2021. Piper Sandler & Co. is the lead bookrunner.
Catalyst Biosciences (NASDAQ: CBIO) has announced an underwritten public offering of its common stock, with market conditions influencing the amount and terms. The company may grant underwriters a 30-day option to purchase an additional 15% of shares. Proceeds will support general corporate purposes, including research and development in hemophilia and complement programs, capital expenditures, and operational costs. The offering will use a previously filed effective registration statement. Piper Sandler & Co. and Raymond James & Associates are involved as bookrunners.
Catalyst Biosciences (NASDAQ: CBIO) announced two e-poster presentations at the EAHAD Virtual Congress occurring from February 3-5, 2021. The posters highlight the effectiveness of Marzeptacog Alfa (Activated) for treating spontaneous bleeding in both hemophilia A rats and dogs. Presenters include Tom Knudsen and Howard Levy, with accessible materials post-event on the Catalyst website.
Additionally, Catalyst is focused on developing solutions for rare coagulation disorders and has a partnership with Biogen for complement-related therapies.
Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced participation in a fireside chat hosted by LifeSci Capital on January 19, 2021, at 1:00 pm ET. Management will discuss new complement programs and developments surrounding CB 2782, a C3 degrader partnered with Biogen, and MarzAA, a late-stage asset for hemostasis. The call registration can be accessed via email, with a replay available on the company's website for 90 days. Catalyst focuses on rare disorders of the complement and coagulation systems, boasting two late-stage clinical programs, including MarzAA.
Catalyst Biosciences (NASDAQ: CBIO) presented its Phase 3 study, Crimson 1, at the ASH meeting on December 7, 2020. The study evaluates Marzeptacog alfa (activated), a subcutaneous therapy for treating bleeding in patients with Hemophilia A or B with inhibitors. It aims to demonstrate non-inferiority compared to Standard of Care, enrolling about 60 subjects and treating 244 bleeding episodes. The primary endpoint is effective hemostasis at 24 hours. CEO Nassim Usman stated that MarzAA could be a significant addition to hemophilia treatment options.
Catalyst Biosciences, Inc. (NASDAQ: CBIO) will host a research and development call on December 14, 2020, at 12:00 pm ET regarding its systemic complement regulator programs. Management will introduce their first subcutaneously-dosed systemic complement candidate and provide insights on their protease engineering platform that targets various diseases. The call will feature Ronald P. Taylor, Ph.D., who will discuss complement-related diseases. This information will be available on their website for 90 days.
Catalyst Biosciences has received FDA Fast Track Designation for Marzeptacog alfa (MarzAA), an innovative subcutaneous treatment for episodic bleeding in Hemophilia A or B patients with inhibitors. The designation aims to expedite development for addressing unmet medical needs. A pivotal Phase 3 study, CRIMSON 1, will begin this month, assessing MarzAA's safety and efficacy compared to Standard of Care. The trial aims to enroll 60 subjects, aiming for effective hemostasis in treated bleeding episodes. This designation may enhance MarzAA's market accessibility and importance in hemophilia treatment.
FAQ
What is the market cap of Catalyst Biosciences (cbio)?
What does Catalyst Biosciences, Inc. specialize in?
What is hemophilia?
What is a protease?
What are the recent achievements of Catalyst Biosciences?
How does Catalyst Biosciences fund its projects?
What is the current focus of Catalyst Biosciences' research?
How can I stay updated with the latest news about Catalyst Biosciences?
What stage are Catalyst Biosciences' therapies currently in?
Why are strategic partnerships important for Catalyst Biosciences?
How does Catalyst Biosciences' approach benefit patients?
